VYNE Therapeutics to Participate in September Investor Conferences
BRIDGEWATER, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that management will participate in two investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024, New York, NY Format: One-on-one investor meetings Stifel 2024 Virtual Immunology and Inflammation Summit September 17-18, 2024 Presentation: Tuesday, September 17, 2024 at 8:30 AM ET Format: Fireside Chat and one-on-one investor meetings Registration: Webcast link A webcast replay will be available on…